DR3/TNFRSF25 Antibody (59204) [Unconjugated]

Western blot shows lysates of human CD8+ T cells. PVDF membrane was probed with 2 µg/mL of Mouse Anti-Human/Mouse DR3/TNFRSF25 Monoclonal Antibody (Catalog # MAB943) followed by HRP-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # HAF018). A specific band was detected for DR3/TNFRSF25 at approximately 55 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1.

Mouse splenocytes either (A) untreated or (B) treated with PMA and Calcium Ionomycin for 24 hours were stained with Mouse Anti-Human DR3/TNFRSF25 Monoclonal Antibody (Catalog # MAB943) followed by Allophycocyanin-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # F0101B) and Rat Anti-Mouse CD3 PE‑conjugated Monoclonal Antibody (Catalog # FAB4841P). Quadrant markers were set based on control antibody staining (Catalog # MAB002).

Human peripheral blood mononuclear cells (PBMCs) either (A) untreated or (B) treated with PMA and Calcium Ionomycin for 24 hours were stained with Mouse Anti-Human DR3/TNFRSF25 Monoclonal Antibody (Catalog # MAB943) followed by Phycoerythrin-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # F0102B) and Mouse Anti-Human CD3 epsilon APC‑conjugated Monoclonal Antibody (Catalog # FAB100A). Quadrant markers were set based on control antibody staining (Catalog # MAB002).

• Reactivity: Hu, Mu
• Applications: WB, Flow, CyTOF-ready
• Clone: 59204
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Unconjugated

DR3/TNFRSF25 Antibody (59204) [Unconjugated] Summary

• Immunogen: Mouse myeloma cell line NS0-derived recombinant human DR3 isoform 1
  Gln25-Phe201
  Accession # Q93038
• Specificity: Detects human DR3/TNFRSF25 in direct ELISAs and Western blots. Shows 100% cross-reactivity with recombinant mouse (rm) DR3/TNFRSF25 and no cross-reactivity with recombinant human (rh) 4-1BB, rhCD27, rhCD30, rhCD40, rhDR6, rhBAFF R, rhFas, rhGITR, rhLTR beta , rhNGF R, rhOPG, rmOX40, rhRANK, rhTAJ, rhTNF RI, rhTNF RII, or rhHVEM.
• Source: N/A
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse
• Gene: TNFRSF25
• Purity Statement: Protein A or G purified from ascites

Applications/Dilutions

• Dilutions:
  • CyTOF-ready
  • Flow Cytometry 0.25 ug/10^6 cells
  • Western Blot 2 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Reconstitution Instructions: Reconstitute at 0.5 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for DR3/TNFRSF25 Antibody (59204) [Unconjugated]

• APO3
• Apo-3
• Apoptosis-inducing receptor AIR
• Apoptosis-mediating receptor DR3
• Apoptosis-mediating receptor TRAMP
• Death receptor 3
• DR3
• DR3member 12 (translocatingchain-association membrane protein)
• LARD
• Lymphocyte-associated receptor of death
• Protein WSL
• Protein WSL-1
• TNFRSF25
• TRAMP
• tumor necrosis factor receptor superfamily, member 25
• WSL
• WSL1
• WSL-1

Background

Death receptor 3 (DR3), also known as lymphocyte-associated receptor of death (LARD), WSL-1, APO3, TRAMP and TR3, is a glycoprotein belonging to the TNF receptor superfamily (TNFRSF) (1 - 5). DR3 was formerly designated TNFRSF12 when it was thought to be a receptor for TWEAK/TNFSF12 (6). However, work disavowed the DR3:TWEAK interaction and DR3 is now designated TNFRSF 25 (7). By alternative splicing, at least 11 distinct human DR3 transcripts encoding secreted or type I membrane proteins exist (7). The human DR3 isoform 1 cDNA encodes a 417 amino acid residue (aa) transmembrane precursor with a 24 aa signal peptide, a 175 aa extracellular domain containing four cysteine-rich repeats and two potential N-glycosylation sites, a 21 aa transmembrane region and a 195 aa cytoplasmic region with one death domain. DR3 is one of six within the TNF R superfamily that contains a death domain in its cytooplasmic region. It is most closely related to TNF R1 and FAS/CD95, sharing 29% and 23% aa sequence identity, respectively. DR3 is expressed primarily in tissues enriched in lymphocytes. Whereas naïve B and T cells express multiple truncated DR3 isoforms but not the transmembrane isoform 1, upon T cell activation, expression of the transmembrane DR3 isoform 1 predominates. TL1A/VEGI, a TNF superfamily ligand, has been shown to bind and activate DR3 (8). Depending on the cell context, ligation of DR3 by TL1A can trigger one of two signaling pathways. On primary T cells, TL1A induces NF-kappa-B activation and a costimulatory signal to increase IL-2 responsiveness and the secretion of proinflammatory cytokines. However, in a tumor cell line, TF-1, TL1A has been shown to induce caspase activity and apoptosis. In DR3-null mice, an impairment of negative selection and anti-CD3-mediated thymocyte apoptosis is observed.

1. Chinnaiyan, A.M. et al. (1996) Science 274:990.
2. Kitson, J. et al. (1996) Nature 384:372.
3. Bodmer, J-L. et al. (1997) Immunity 6:79.
4. Screaton, G.R. et al. (1997) Proc. Nat. Acad. Sci. USA 94:4615.
5. Marsters, S.A. et al. (1996) Curr. Biol. 6:1669.
6. Marsters, S.A. et al. (1998) Curr. Biol. 8:525.
7. Kaptein, A. et al. (2000) FEBS Lett. 485:135.
8. Migone, T-S. et al. (2002) Immunity 16:479.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for DR3/TNFRSF25 Antibody (MAB943)(2)

Publications using MAB943

• Porquet N, Poirier A, Houle F, Pin AL, Gout S, Tremblay PL, Paquet ER, Klinck R, Auger FA, Huot J Survival advantages conferred to colon cancer cells by E-selectin-induced activation of the PI3K-NFkappaB survival axis downstream of Death receptor-3. BMC Cancer, 2011-07-01;11(0):285. 2011-07-01 [PMID: 21722370] (Neutralization, Human)
• Yang CR, Ho FM, Su WL Soluble decoy receptor 3 induces angiogenesis by neutralization of TL1A, a cytokine belonging to tumor necrosis factor superfamily and exhibiting angiostatic action. Cancer Res., 2004-02-01;64(3):1122-9. 2004-02-01 [PMID: 14871847] (Western Blot, Human)

Bioinformatics

• Gene Symbol: TNFRSF25
• Uniprot:
  • Q93038()